processes and the prediction of prognosis may be facilitated by characterizing the cellular composition of the tissue. 6,7 19 F-CMR can visualize 19 F-containing molecules, which are incorporated into specific cell types, i.e. it can detect and track 19 F-labeled cells non-invasively in the intact body ( Figure 1 
The PFC family-a field of research
In their study, Boenner et al. used a particular PFC, perfluoro-octyl bromide (PFOB) with a biological half-life of 3-8 days, 8 which is ideal to monitor cells over hours to days following injection. Interestingly, this compound is also considered safe, as it passed already Phase III clinical trials in the field of surgery, as this compound can facilitate oxygen transport in blood. It was therefore tested as a plasma expander by administration of large volumes of PFOB to patients. It is also possible to follow migration of different cell types by 19 F-MRI simultaneously by using various PFCs which differ in their resonance frequency spectrum. 10 Another research activity is exploring the effect of shortening the relaxation time of PFC by introducing gadolinium into the PFC, thereby increasing the signal of the PFCs. 11 In the present study by Boenner et al., the PFOB was injected intravenously and the source of the 19 F signal in the heart was the macrophage population which had incorporated the circulating PFOB. Other PFCs are designed for labelling various cell types in vitro. Once labelled in vitro, these specific cell types can be injected into the 
F-MR imaging of PFCs
While the PFOB features a favourable safety profile and a biological half-life to monitor cells over several days, its resonance spectrum is composed of several peaks which is challenging from a MR imaging perspective. To solve this problem, the authors of the current paper developed an elegant MR pulse sequence, which can handle the multi-peak spectrum of PFOB, and thus, they present in their paper a major step forward in the 19 F-MRI development. Never- F technique were performed on high-field MR scanners (of 9T and higher) using small animal models. This current study is one of the first to demonstrate the feasibility to achieve a cellular characterization of the myocardium by the 19 F technique on a clinical 3T MR scanner. In their study, they convincingly confirmed their 19 F-MRI results with immunohistological and flow cytometry data. As no radiation is involved in this type of cell tracking, there appears a bright future for this technique to successfully be translated into clinical routine.
Perspectives
In summary, the study of Boenner and colleagues convincingly demonstrates the potential of the PFOB for cellular characterization, when combined with a novel MR pulse sequence scheme and by translating this approach onto a 3T clinical MR machine. Hopefully, the presented findings will further accelerate the transition of this technique from high-field small animal experiments to clinical studies in patients. Once available in patients this 19 F-MRI technique could represent a powerful tool to localize the site of inflammation and to quantify and monitor the response to treatment, e.g. in myocarditis but also in the setting of fever of unknown origin and in other inflammatory diseases. This tool may also allow to studying autoimmune diseases in more detail and could be of great value in the design and monitoring of immunotherapies in cancer patients. Finally, the concept of targeted PFC emulsions could substantially enhance our armamentarium to detect thrombi or other specific targets in the human body. As this technique is radiation free and can monitor cells over hours and days, there is a bright future for this technique to improve diagnosis and to monitor treatment responses in patients. Editorial
